US1928346A - Anaesthetic - Google Patents

Anaesthetic Download PDF

Info

Publication number
US1928346A
US1928346A US500427A US50042730A US1928346A US 1928346 A US1928346 A US 1928346A US 500427 A US500427 A US 500427A US 50042730 A US50042730 A US 50042730A US 1928346 A US1928346 A US 1928346A
Authority
US
United States
Prior art keywords
ether
acid
ethyl
mixture
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US500427A
Inventor
Meyer L Axelrod
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HARRY FRAIBERG
Original Assignee
HARRY FRAIBERG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HARRY FRAIBERG filed Critical HARRY FRAIBERG
Priority to US500427A priority Critical patent/US1928346A/en
Application granted granted Critical
Publication of US1928346A publication Critical patent/US1928346A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60Three or more oxygen or sulfur atoms
    • C07D239/62Barbituric acids

Definitions

  • morphine or similar narcotics In actual use, the patient is first given enemas administrations are apt to have an undesired until the return is clear, after which the barbieilect upon the patient and the child and does not turic preparation is instilled. The instillation of always serve the intended purpose.
  • the barbituric compound may be preceded by an It is therefore one of the objects of my invenounce of plain oil, also Vaseline is applied to the 70 tion to provide a hypnotic compound which may anus to prevent possible irritation should the be administered to the patient in the first stage compound be expelled.
  • the compound may include a mixture of vide an anasthetic which may be easily and safemineral oil, ether, quinine and a barbiturate.
  • the ly administered to the patient and which tends to oil used may be either a mineral oil or vegetable eliminate the nervous condition which sometimes 011 uc a Olive HOWEVBI', mineral Oil is p accompany the administration of anaesthetics. fcrred as it does not tend to turn rancid.
  • Another object of my invention is to provide an also to be understood that the proportions of anaesthetic which may be administered during the the ingredients in the compound may be varied first stages of labor and which is sufliciently lastto procure difierent degrees of anaesthesia. ing in its efiects to maintain the patient under I have observed in my various experiences at its analgesic influence throughout the entire dethe solution can be made either with or without 1ivery the aid of solvents other than the ether.
  • ethyl (lmethylbutyl) barbituric acid is representative of a quick acting barbiturate which takes effect very shortly after administration, whereas the other is representative of a relatively slow acting barbiturate which in this instance may involve twice as much time before it becomes effective.
  • This mixture may be administered as previously described and is particularly adaptable for analgesia during childbirth.
  • the average patient Upon instillation of the above dosage, the average patient is susceptible to from 10 to 18 hours of complete amnesia and analgesia.
  • a compound made in accordance with my invention, from which the quinine is omitted may also be used for surgery.
  • a particular combination for such use may be 2% ounces ether, 1%; ounces mineral oil and 10 grains of nembutal. It is very apparent-that the increased proportions of the barbiturate will give more complete anaesthesia.
  • the dosage may be regulated according to body Weight, a patient weighing 130 pounds or over receiving the full 4 ounce mixture; those between 100 and 130 pounds receiving approximately of the contents and those under 100 pounds receiving /2 of the contents.
  • a hypnotic compound for rectal instillation comprising a solution of oil, ether and a barbiturate.
  • a hypnotic compound for rectal instillation comprising a mixture of oil and ether and an oil and ether soluble barbiturate.
  • a hypnotic compound for rectal instillation comprising a mixture of mineral oil and ether and an oil and ether soluble barbiturate.
  • a hypnotic compound for rectal instillation comprising a mixture of mineral oil and ether and a barbiturate.
  • a hypnotic compound for rectal instillation comprising a mixture of oil, ether and two or more of the barbiturates.
  • a hypnotic compound for rectal instillation comprising a mixture of oil, ether and oil and ether soluble barbiturates.
  • a hypnotic compound for rectal instillation comprising a mixture of oil, ether, and ethyl (1-methyl butyl) barbituric acid-and n-butylethyl-barbituric-acid.
  • a hypnotic compound for rectal instillation comprising a mixture of mineral oil, ether and ethyl (l-methyl butyl) barbituric-acid.
  • A-hypnotic compound for rectal instillation comprising a mixture of mineral oil, ether and n-butylethylbarbituric-acid.
  • a hypnotic compound for rectal instillation comprising a mixture of mineral oil, ether and ethyl (l-methyl butyl) barbituric-acid and n-butyl-ethyl-barbituric-acid.
  • An analgesic comprising a mixture in the proportions-mineral oil 1 /2 ounces, ether 2%; ounces, and ethyl (l-methyl butyl) barbituricacid 8 grains and n-butyl-ethyl-barbituric-acid

Description

Patented Sept. 26. 1933 1 1,928,346
ANZESTHETIC Meyer L. Axelrod, Cleveland, Ohio, assignor of gfltiy per cent to Harry Fraiberg, Cleveland,
No Drawing. Application December 5, 1930 Serial No. 500,427
12 Claims. (Cl. 167-52) My invention relates to improvements in hyp- Phanodorn cyclohexenyl ethyl barbiturio notic compounds, particularly analgesics and acid. anaesthetics. In the administration of anaes- Amytal-isoamyl ethyl barbituric acid.
thetics or analgesics, particularly for obstetrical Ipral (acid form)-ethyl isopropyl barbituric operations, the usual practice has been to await acid.
until a certain amount of dilation of the cervix Pernokton-secondary butyl bromallyl barbihas taken place before administering the particuturic acid. lar anaesthetic. It is common knowledge that the Phenobarbital-phenyl ethyl barbituric acid labor pains prior to the aforesaid dilation are (Luminal).
0 excruciating but may be relieved by the use of Barbital-diethyl barbituric acid (Veronal). 65
morphine or similar narcotics. However, such In actual use, the patient is first given enemas administrations are apt to have an undesired until the return is clear, after which the barbieilect upon the patient and the child and does not turic preparation is instilled. The instillation of always serve the intended purpose. the barbituric compound may be preceded by an It is therefore one of the objects of my invenounce of plain oil, also Vaseline is applied to the 70 tion to provide a hypnotic compound which may anus to prevent possible irritation should the be administered to the patient in the first stage compound be expelled. A slow uniform rate of of labor to permit uterine contractions and relieve instillation is established and the mixture perthe initial pains as well as the pains in the other mitted to enter the colon between uterine constages of labor. traCtiOnS- 5 Still another object of my invention is to pro- The compound may include a mixture of vide an anasthetic which may be easily and safemineral oil, ether, quinine and a barbiturate. The ly administered to the patient and which tends to oil used may be either a mineral oil or vegetable eliminate the nervous condition which sometimes 011 uc a Olive HOWEVBI', mineral Oil is p accompany the administration of anaesthetics. fcrred as it does not tend to turn rancid. It is I am aware that ether and oil with quinine have may be more quickly put into solution by using a Another object of my invention is to provide an also to be understood that the proportions of anaesthetic which may be administered during the the ingredients in the compound may be varied first stages of labor and which is sufliciently lastto procure difierent degrees of anaesthesia. ing in its efiects to maintain the patient under I have observed in my various experiences at its analgesic influence throughout the entire dethe solution can be made either with or without 1ivery the aid of solvents other than the ether. In
Still other objects and uses of my new comsome ether the alcohol content is relatively high pound will become apparent from the following and therefore the quinine is more expeditiously description thereof. put into solution. I also find that the quinine been heretofore administered to the patient by small amount of other solvents, such as ethyl rectal instillation for obtaining analgesia; howalcohol, and when so used, I find that approxiever, as previously stated, this administration mately three fluid drains of ethyl alcohol in a cannot be applied with success to the patient unfour fluid ounce solution of the compound is sufiitil after the first stages of labor have passed becient for all purposes of solubility. cause of the short duration of its eflect. I am I have found that a mixture of 1 ounces also aware that barbiturates have been used with mineral oil, 2 ounces ether, 20 grains quinine inhalation anaesthetics. I believe the use of the alkaloid, together with a mixture of two barbitubarbiturates in the manner which I am about to rates which are known to the profession as disclose, is distinctly new. There are at the presnembutal (acid form) and neonal, which barbi- 190 ent time, a number of commercial barbiturates, u a s a et y (l-mcthyl y barbitulic some of which better suit themselves than others, acid, and n-butyl ethyl barbituric acid respecto my particular compound. Among the more tively, in the proportion of 8 grains nembutal useful barbiturates I have used are the following: (acid form) and 5 grains neonal produce a very 0 Nembutal (acid form)-ethyl (l-methyl butyl) satisfactory result. I find that a combination barbituric acid. of two or more barbiturates as described is some- Neonaln-butyl ethyl barbituric acid. times desirable. The effect is not additive but Allonala1lyl isopropyl barbituric acid plus due to the synergetic action between the two bar- 5 amidopyrine. biturates, each barbiturate enhances the action o Dial-diallyl barbituric acid. of the other, causing a substantially different eifect than is found from the use of either one alone. In the foregoing example ethyl (lmethylbutyl) barbituric acid is representative of a quick acting barbiturate which takes effect very shortly after administration, whereas the other is representative of a relatively slow acting barbiturate which in this instance may involve twice as much time before it becomes effective. This mixture may be administered as previously described and is particularly adaptable for analgesia during childbirth. Upon instillation of the above dosage, the average patient is susceptible to from 10 to 18 hours of complete amnesia and analgesia.
A compound made in accordance with my invention, from which the quinine is omitted may also be used for surgery. A particular combination for such use may be 2% ounces ether, 1%; ounces mineral oil and 10 grains of nembutal. It is very apparent-that the increased proportions of the barbiturate will give more complete anaesthesia. The dosage may be regulated according to body Weight, a patient weighing 130 pounds or over receiving the full 4 ounce mixture; those between 100 and 130 pounds receiving approximately of the contents and those under 100 pounds receiving /2 of the contents.
In actual use it has been found that the patient usually becomes drowsy within 30 minutes and gradually goes into a deep slumber. In time, (1 hour) most patients can be aroused but with great difliculty and the uterine contractions appear to be accelerated rather than interfered with. The dosage of the barbiturates may in some cases be regulated in such a manner that a supplemental anaesthesia may be required. The use of a compound as described, eliminates the use of drugs which may seriously afiect the baby or patient. It will also reduce the post operative need of narcotics. The pulse, respiration and blood pressure are not materially affected. The blood loss is not affected. Uterine contractions are not interfered with and the patient has no recollection of labor pains. No undesirable after effects have been observed.
Having thus described my compound and its method of use, I am aware that the exact proportions of the various ingredients may be varied, and should be varied to suit different cases, but
that such variation is well within the precepts of the invention and such as may be understood to those experienced in such matters and does not depart from the spirit of myinvention nor the scope of the appended claims.
I claim:
1. A hypnotic compound for rectal instillation comprising a solution of oil, ether and a barbiturate.
2. A hypnotic compound for rectal instillation comprising a mixture of oil and ether and an oil and ether soluble barbiturate.
3. A hypnotic compound for rectal instillation comprising a mixture of mineral oil and ether and an oil and ether soluble barbiturate.
4. A hypnotic compound for rectal instillation comprising a mixture of mineral oil and ether and a barbiturate.
5. A hypnotic compound for rectal instillation comprising a mixture of oil, ether and two or more of the barbiturates.
6 A hypnotic compound for rectal instillation comprising a mixture of oil, ether and oil and ether soluble barbiturates.
7. A hypnotic compound for rectal instillation comprising a mixture of oil, ether, and ethyl (1-methyl butyl) barbituric acid-and n-butylethyl-barbituric-acid.
8. A hypnotic compound for rectal instillation comprising a mixture of mineral oil, ether and ethyl (l-methyl butyl) barbituric-acid.
9. A-hypnotic compound for rectal instillation comprising a mixture of mineral oil, ether and n-butylethylbarbituric-acid.
10. A hypnotic compound for rectal instillation comprising a mixture of mineral oil, ether and ethyl (l-methyl butyl) barbituric-acid and n-butyl-ethyl-barbituric-acid.
11. An analgesic comprising a mixture in the proportions-mineral oil 1 /2 ounces, ether 2%; ounces, and ethyl (l-methyl butyl) barbituricacid 8 grains and n-butyl-ethyl-barbituric-acid
US500427A 1930-12-05 1930-12-05 Anaesthetic Expired - Lifetime US1928346A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US500427A US1928346A (en) 1930-12-05 1930-12-05 Anaesthetic

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US500427A US1928346A (en) 1930-12-05 1930-12-05 Anaesthetic

Publications (1)

Publication Number Publication Date
US1928346A true US1928346A (en) 1933-09-26

Family

ID=23989371

Family Applications (1)

Application Number Title Priority Date Filing Date
US500427A Expired - Lifetime US1928346A (en) 1930-12-05 1930-12-05 Anaesthetic

Country Status (1)

Country Link
US (1) US1928346A (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2603583A (en) * 1949-03-04 1952-07-15 Welch Henry Pectin penicillin preparation
US2619447A (en) * 1949-03-11 1952-11-25 American Cyanamid Co Injectable penicillin preparations
US2736682A (en) * 1954-10-11 1956-02-28 Victor M Hermelin Method of making a prolonged action medicinal tablet
US2793979A (en) * 1953-03-30 1957-05-28 Smith Kline French Lab Method of making a sustained release pharmaceutical tablet and product of the method
US2824546A (en) * 1950-10-20 1958-02-25 Klette Hermann Treating animals with hormone preparation
US2839447A (en) * 1955-01-07 1958-06-17 Riedelde Haen Ag Intravenous ultrashort-acting anesthetic composition
US3075983A (en) * 1963-01-29 -oconh
US3108997A (en) * 1957-10-31 1963-10-29 Astra Ab Morpholino lower alkanoyl xylidides and toluidides
US5252577A (en) * 1992-03-06 1993-10-12 Gillette Canada, Inc. Methods of desensitizing teeth
US5660817A (en) * 1994-11-09 1997-08-26 Gillette Canada, Inc. Desensitizing teeth with degradable particles

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3075983A (en) * 1963-01-29 -oconh
US2603583A (en) * 1949-03-04 1952-07-15 Welch Henry Pectin penicillin preparation
US2619447A (en) * 1949-03-11 1952-11-25 American Cyanamid Co Injectable penicillin preparations
US2824546A (en) * 1950-10-20 1958-02-25 Klette Hermann Treating animals with hormone preparation
US2793979A (en) * 1953-03-30 1957-05-28 Smith Kline French Lab Method of making a sustained release pharmaceutical tablet and product of the method
US2736682A (en) * 1954-10-11 1956-02-28 Victor M Hermelin Method of making a prolonged action medicinal tablet
US2839447A (en) * 1955-01-07 1958-06-17 Riedelde Haen Ag Intravenous ultrashort-acting anesthetic composition
US3108997A (en) * 1957-10-31 1963-10-29 Astra Ab Morpholino lower alkanoyl xylidides and toluidides
US5252577A (en) * 1992-03-06 1993-10-12 Gillette Canada, Inc. Methods of desensitizing teeth
US5660817A (en) * 1994-11-09 1997-08-26 Gillette Canada, Inc. Desensitizing teeth with degradable particles
US5741479A (en) * 1994-11-09 1998-04-21 Gillette Canada Inc. Desensitizing teeth with degradable particles

Similar Documents

Publication Publication Date Title
Foss et al. Oral methyltestosterone and jaundice
Forster et al. IV midazolam as an induction agent for anaesthesia: a study in volunteers
SADOVE et al. Analgesic effects of ketamine administered in subdissociative doses
US1928346A (en) Anaesthetic
Dundee et al. Comparison of the actions of diazepam and lorazepam
Hamilton et al. Expectorant action of bromhexine in chronic obstructive bronchitis
Godlowski Eosinopenia caused by Adrenaline and Insulin
Eger et al. Etiology of varicose veins from an anatomic aspect, based on a dissection of thirty-eight adult cadavers
Redfern et al. Incremental propofol for short procedures
DE3317692A1 (en) USE OF METKEPHAMIDE OR A PHARMACEUTICALLY SAFE SALT THEREOF AS AN ANALGETIC IN SUBSTANTIVE FEMALE ANIMALS AND ESPECIALLY IN PREGNANT WOMEN
FRIEDMAN et al. THE HYPERTENSIVE EFFECT OF COMPOUND FACETATE (17-OH-CORTICOSTERONE-21-ACETATE) IN THfi RAT
Grossman et al. The pepsin content of gastric juice secreted in response to hormonal stimulation
Roby et al. Demerol (S-140) and scopolamine in labor: A preliminary report
DD238921A5 (en) METHOD FOR PRODUCING A CONTRAZEPTIVE SYNERGISTIC COMPOSITION
ALBERT et al. Fluothane for obstetric anesthesia
OLIVER-GONZÁLEZ et al. TREATMENT OF FILARIASIS BANCROFTI WITH HETRAZAN®: Follow-up Observations Fifteen Months After Treatment
MILLS et al. Observations on acute leukemia in children treated with 4-aminopteroylglutamic acid
Carr Neurologic syndromes associated with hypoglycemia
Minard et al. Thymoxyethyldiethylamine antagonism to circulatory effects of histamine in anesthetized and nonanesthetized dogs
FRIEDGOOD Similarity of the iodin remission in experimental anterior hypophyseal hyperthyroidism, the hyperthyroidism of acromegaly and that of exophthalmic goiter
Ettelson Inability of desoxycorticosterone acetate to protect adrenalectomized rats against typhoid vaccine
Helfrich et al. Cortical extract in the treatment of shock: Preliminary report
BERGNER et al. the circulatory effects of PROMETHAZINE during spinal anesthesia: a clinical study
WEISS Persistence of Action of Physostigmin and the Atropinphysostigmine Antagonism in Animals and in Man
DUNDEE et al. CLINICAL STUDIES OF INDUCTION AGENTS XX: A METHOHEXITONE-PROPANIDID MIXTURE